BR112018008506B8 - Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos - Google Patents

Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos

Info

Publication number
BR112018008506B8
BR112018008506B8 BR112018008506A BR112018008506A BR112018008506B8 BR 112018008506 B8 BR112018008506 B8 BR 112018008506B8 BR 112018008506 A BR112018008506 A BR 112018008506A BR 112018008506 A BR112018008506 A BR 112018008506A BR 112018008506 B8 BR112018008506 B8 BR 112018008506B8
Authority
BR
Brazil
Prior art keywords
factor xia
pharmaceutical composition
compounds
inhibitor compounds
xia inhibitor
Prior art date
Application number
BR112018008506A
Other languages
English (en)
Other versions
BR112018008506A2 (pt
BR112018008506B1 (pt
Inventor
Amjad Ali
Bart Harper
Cheng Zhu
Dong-Ming Shen
Eric Mertz
Jiayi Xu
Meng Yang
F Neelamkavil Santhosh
D Edmondson Scott
Thomas Bara
Wanying Sun
Wei Zhou
Weiguo Liu
Yeon-Hee Lim
Ying-Duo Gao
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112018008506A2 publication Critical patent/BR112018008506A2/pt
Publication of BR112018008506B1 publication Critical patent/BR112018008506B1/pt
Publication of BR112018008506B8 publication Critical patent/BR112018008506B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Abstract

compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos. a presente invenção proporciona um composto de fórmula (i) e composições farmacêuticas compreendendo um ou mais dos referidos compostos, e métodos para usar os referidos compostos para tratar ou prevenir tromboses, embolias, hipercoagulabilidade ou alterações fibróticas. os compostos são inibidores seletivos do fator xia ou inibidores duais do fator xia e calicreína plasmática.
BR112018008506A 2015-10-29 2016-10-24 Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos BR112018008506B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248075P 2015-10-29 2015-10-29
US62/248,075 2015-10-29
PCT/US2016/058362 WO2017074832A1 (en) 2015-10-29 2016-10-24 FACTOR XIa INHIBITORS

Publications (3)

Publication Number Publication Date
BR112018008506A2 BR112018008506A2 (pt) 2018-10-23
BR112018008506B1 BR112018008506B1 (pt) 2023-11-14
BR112018008506B8 true BR112018008506B8 (pt) 2023-12-05

Family

ID=58631804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008506A BR112018008506B8 (pt) 2015-10-29 2016-10-24 Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos

Country Status (12)

Country Link
US (1) US10214512B2 (pt)
EP (1) EP3368036B1 (pt)
JP (1) JP6892858B2 (pt)
KR (1) KR20180073602A (pt)
CN (1) CN108430471B (pt)
AU (1) AU2016344476B2 (pt)
BR (1) BR112018008506B8 (pt)
CA (1) CA2998902C (pt)
MA (1) MA43128A (pt)
MX (1) MX2018005045A (pt)
RU (1) RU2728783C2 (pt)
WO (1) WO2017074832A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086416A1 (en) * 2018-10-25 2020-04-30 Merck Sharp & Dohme Corp. FACTOR Xla INHIBITORS
JP7270770B2 (ja) 2019-04-16 2023-05-10 チャイナ・リソースズ・バイオファーマシューティカル・カンパニー・リミテッド ＸＩａ因子阻害剤としての大環状誘導体
CN114008047B (zh) * 2019-07-23 2023-03-21 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
CA3206548A1 (en) * 2021-01-28 2022-08-04 John S. Debenham Factor xia inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227269A1 (en) 2000-11-07 2002-06-03 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
WO2002037937A2 (en) 2000-11-07 2002-05-16 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ　スクイブ　カンパニー ファクターＸａ阻害剤のスルホンアミドラクタムおよびその方法
AU2002331707A1 (en) 2001-08-20 2003-03-03 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as antithrombotic agents
EP1523483A4 (en) 2002-06-26 2006-03-08 Bristol Myers Squibb Co AMINO-BICYCLIC PYRAZINONE AND PYRIDINONE FOR INHIBITING THE COOKING OF SERIN PROTEASE
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US20060074103A1 (en) 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
ATE405553T1 (de) 2004-12-08 2008-09-15 Bristol Myers Squibb Co Heterocyclische verbindungen als inhibitoren von faktor viia
ES2349428T3 (es) 2005-01-10 2011-01-03 Bristol-Myers Squibb Company Derivados de fenilglicinamida útiles como anticoagulantes.
US7459564B2 (en) 2005-01-13 2008-12-02 Bristol-Myers Squibb Company Substituted biaryl compounds as factor XIa inhibitors
US20060183771A1 (en) 2005-02-17 2006-08-17 Seiffert Dietmar A Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
AU2006240423A1 (en) * 2005-04-20 2006-11-02 Janssen Pharmaceutica, N.V. Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
US8466295B2 (en) 2005-12-14 2013-06-18 Bristol-Myers Squibb Company Thiophene derivatives as factor XIa inhibitors
US7626039B2 (en) 2005-12-14 2009-12-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7829584B2 (en) * 2006-03-21 2010-11-09 Janssen Pharmaceutica Nv Pyridines and pyridine N-oxides as modulators of thrombin
JP5342450B2 (ja) 2006-12-15 2013-11-13 ブリストル−マイヤーズ スクイブ カンパニー 第ＸＩａ因子インヒビターとしてのアリールプロピオンアミド、アリールアクリルアミド、アリールプロピンアミド、またはアリールメチルウレアアナログ
US8367709B2 (en) * 2007-06-13 2013-02-05 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
ES2674745T3 (es) 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) * 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
IN2014CN02805A (pt) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
CN103987697B (zh) 2011-10-14 2017-04-26 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
PT2766346T (pt) 2011-10-14 2017-05-26 Bristol Myers Squibb Co Compostos de tetrahidroisoquinolina substituídos como inibidores do fator xia
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
CA2880866A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
KR20240017118A (ko) * 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
NO2760821T3 (pt) * 2014-01-31 2018-03-10
US9663527B2 (en) * 2014-02-11 2017-05-30 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2015157115A1 (en) * 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US20180162821A1 (en) * 2016-12-14 2018-06-14 Bristol-Myers Squibb Company Factor xia macrocycles with novel p1 groups

Also Published As

Publication number Publication date
US20180339977A1 (en) 2018-11-29
WO2017074832A1 (en) 2017-05-04
CA2998902A1 (en) 2017-05-04
MX2018005045A (es) 2018-08-01
JP6892858B2 (ja) 2021-06-23
RU2728783C2 (ru) 2020-07-31
RU2018119015A3 (pt) 2020-02-18
JP2018531954A (ja) 2018-11-01
BR112018008506A2 (pt) 2018-10-23
RU2018119015A (ru) 2019-11-29
MA43128A (fr) 2018-09-05
CN108430471A (zh) 2018-08-21
CA2998902C (en) 2024-03-26
AU2016344476A1 (en) 2018-03-08
AU2016344476B2 (en) 2020-08-13
EP3368036A1 (en) 2018-09-05
US10214512B2 (en) 2019-02-26
EP3368036A4 (en) 2019-04-17
KR20180073602A (ko) 2018-07-02
CN108430471B (zh) 2021-07-09
BR112018008506B1 (pt) 2023-11-14
EP3368036B1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
EA201891057A1 (ru) Композиции и способы для ингибирования активности аргиназы
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691134A1 (ru) Новые ингибиторы глутаминазы
PH12018500408A1 (en) Bicyclic compounds as atx inhibitors
BR112015032595A8 (pt) inibidores de ido
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
BR112018006034A2 (pt) compostos bicíclicos como inibidores de atx
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EA201591889A1 (ru) 6-(5-гидрокси-1h-пиразол-1-ил)никотинамидные ингибиторы phd
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201890592A1 (ru) Жидкие фармацевтические композиции, содержащие ингибиторы sglt-2
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017015431A2 (pt) composto, composição farmacêutica, métodos para inibir a formação de trombos no sangue ou tratar uma formação de trombos no sangue, para impedir a formação de trombos no sangue, para tratar tromboembolismo venoso e embolia pulmonar, para tratar trombose venosa profunda e para tratar ataque tromboembólico, e, uso de um composto
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
BR112017022269A2 (pt) métodos para tratar câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2016, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2758 DE 14/11/2023, QUANTO AO ITEM (73) ENDERECO DO TITULAR.